ATE445701T1 - Zytokine rezeptor zcytor19 - Google Patents

Zytokine rezeptor zcytor19

Info

Publication number
ATE445701T1
ATE445701T1 AT01988203T AT01988203T ATE445701T1 AT E445701 T1 ATE445701 T1 AT E445701T1 AT 01988203 T AT01988203 T AT 01988203T AT 01988203 T AT01988203 T AT 01988203T AT E445701 T1 ATE445701 T1 AT E445701T1
Authority
AT
Austria
Prior art keywords
polypeptides
zcytor19
methods
cytokine receptor
vitro
Prior art date
Application number
AT01988203T
Other languages
English (en)
Inventor
Scott Presnell
Wenfeng Xu
Julia Novak
Theodore Whitmore
Francis Grant
Original Assignee
Zymogenetics L L C
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics L L C, Bristol Myers Squibb Co filed Critical Zymogenetics L L C
Application granted granted Critical
Publication of ATE445701T1 publication Critical patent/ATE445701T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurology (AREA)
  • Cell Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • AIDS & HIV (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
AT01988203T 2000-11-28 2001-11-28 Zytokine rezeptor zcytor19 ATE445701T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25356100P 2000-11-28 2000-11-28
US26721101P 2001-02-07 2001-02-07
PCT/US2001/044808 WO2002044209A2 (en) 2000-11-28 2001-11-28 Cytonkine receptor zcytor19

Publications (1)

Publication Number Publication Date
ATE445701T1 true ATE445701T1 (de) 2009-10-15

Family

ID=26943370

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01988203T ATE445701T1 (de) 2000-11-28 2001-11-28 Zytokine rezeptor zcytor19

Country Status (12)

Country Link
US (10) US20030027253A1 (de)
EP (1) EP1356046B1 (de)
JP (1) JP2004532611A (de)
AT (1) ATE445701T1 (de)
AU (1) AU2002241533A1 (de)
CA (1) CA2430485A1 (de)
CY (1) CY1110921T1 (de)
DE (1) DE60140213D1 (de)
DK (1) DK1356046T3 (de)
ES (1) ES2334888T3 (de)
PT (1) PT1356046E (de)
WO (1) WO2002044209A2 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004532611A (ja) 2000-11-28 2004-10-28 ザイモジェネティクス，インコーポレイティド サイトカイン受容体ｚｃｙｔｏｒ１９
TW200300170A (en) * 2001-11-09 2003-05-16 Wyeth Corp Type 2 cytokine receptor and nucleic acids encoding same
US7033787B2 (en) * 2001-12-21 2006-04-25 Ludwig Institute For Cancer Research Isolated cytokine receptor LICR-2
EP2295455A1 (de) * 2002-04-19 2011-03-16 ZymoGenetics, L.L.C. Cytokinrezeptor
US20040170982A1 (en) * 2003-02-14 2004-09-02 Morris David W. Novel therapeutic targets in cancer
US20060246161A1 (en) * 2003-02-21 2006-11-02 Hongtao Xing Method of making medicament for treating anemia
CA2534907C (en) 2003-08-07 2014-04-29 Zymogenetics, Inc. Homogeneous preparations of il-28 and il-29
EP1732946B1 (de) 2004-03-08 2011-07-27 ZymoGenetics, Inc. Dimere fusionsproteine und materialien und verfahren zu deren herstellung
CA2574564C (en) 2004-07-29 2013-04-16 Zymogenetics, Inc. Use of il-28 and il-29 to treat cancer and autoimmune disorders
SI1907382T1 (sl) 2005-07-26 2015-10-30 Bial-Portela & Ca S.A., Nitrokateholni derivati kot inhibitorji COMT
EP1845097A1 (de) 2006-04-10 2007-10-17 Portela & Ca., S.A. Oxadiazolderivate als COMT Inihibitoren
HUE031317T2 (hu) 2007-01-31 2017-07-28 Bial - Portela & Ca S A Specifikus dózisprotokollal adagolt COMT inhibitor nitrokatechin származékok
EP2214703A1 (de) * 2007-10-31 2010-08-11 The Scripps Research Institute Kombinationstherapie zur behandlung von anhaltenden virusinfektionen
CN102438595B (zh) * 2009-04-01 2016-04-27 巴尔-波特拉及康邦亚股份有限公司 包括硝基儿茶酚衍生物的药物制剂及其制备方法
CN102448444B (zh) 2009-04-01 2016-05-25 巴尔-波特拉及康邦亚股份有限公司 包括硝基儿茶酚衍生物的药物制剂及其制备方法
US20140045900A1 (en) 2011-02-11 2014-02-13 Bial-Portela & Ca, S.A. Administration regime for nitrocatechols
EP2718306A1 (de) * 2011-06-13 2014-04-16 Merck Sharp & Dohme Corp. Verfahren zur reinigung nativer oder mutanter formen von diphtherietoxin
HUE047856T2 (hu) 2011-12-13 2020-05-28 Bial Portela & Ca Sa Kémiai vegyület, amely köztitermékként használható katechol-O-metil-transzferáz inhibitor elõállításához
SG11201507432XA (en) * 2013-03-15 2015-10-29 Abbvie Inc Antibody drug conjugate (adc) purification
WO2014182658A1 (en) * 2013-05-06 2014-11-13 Abbvie Inc. Compositions for cell culture and methods of using the same
WO2016033509A1 (en) * 2014-08-29 2016-03-03 The Regents Of The University Of Colorado, A Body Corporate Aquaporin-4 antibodies and uses thereof for the treatment of neuromyelitis optica
JP2018500300A (ja) 2014-11-28 2018-01-11 ノヴィファーマ，エス．アー． パーキンソン病を遅延させるための医薬
JP7323102B2 (ja) * 2016-04-13 2023-08-08 オリマブス リミテッド 抗ｐｓｍａ抗体およびその使用
WO2023049774A1 (en) * 2021-09-21 2023-03-30 University Of Washington Genetically encoded and exogenously triggered protein-protein ligation

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7625697B2 (en) * 1994-06-17 2009-12-01 The Board Of Trustees Of The Leland Stanford Junior University Methods for constructing subarrays and subarrays made thereby
US5945511A (en) * 1997-02-20 1999-08-31 Zymogenetics, Inc. Class II cytokine receptor
US5965704A (en) * 1997-08-05 1999-10-12 Zymogenetics, Inc. Class two cytokine receptor-11
WO2001002568A2 (en) 1999-07-02 2001-01-11 Chiron Corporation Human genes and gene expression products
EP2298789B1 (de) * 2000-09-08 2012-03-14 Schering Corporation Gene von Säugetiere, und damit verbundene Reagentien, Methoden
JP2004532611A (ja) 2000-11-28 2004-10-28 ザイモジェネティクス，インコーポレイティド サイトカイン受容体ｚｃｙｔｏｒ１９
CN101531715A (zh) * 2001-04-20 2009-09-16 津莫吉尼蒂克斯公司 细胞因子蛋白质家族
WO2003031620A1 (fr) 2001-10-02 2003-04-17 Mochida Pharmaceutical Co., Ltd. Nouveau recepteur des cytokines de classe ii
TW200300170A (en) 2001-11-09 2003-05-16 Wyeth Corp Type 2 cytokine receptor and nucleic acids encoding same
US7033787B2 (en) * 2001-12-21 2006-04-25 Ludwig Institute For Cancer Research Isolated cytokine receptor LICR-2
AU2003215136A1 (en) 2002-02-08 2003-09-02 University Of Medicine And Dentistry Of New Jersey Ifn-a/b-independent mechanism of antiviral protection
EP2295455A1 (de) 2002-04-19 2011-03-16 ZymoGenetics, L.L.C. Cytokinrezeptor
AU2003286624B2 (en) 2002-10-23 2008-11-13 Bristol-Myers Squibb Company Methods for treating viral infection using IL-28 and IL-29
US20060228710A1 (en) 2003-02-14 2006-10-12 Morris David W Novel therapeutic targets in cancer

Also Published As

Publication number Publication date
WO2002044209A3 (en) 2003-08-21
WO2002044209A2 (en) 2002-06-06
US20030027253A1 (en) 2003-02-06
ES2334888T3 (es) 2010-03-17
EP1356046A2 (de) 2003-10-29
US7618791B2 (en) 2009-11-17
US20070117165A1 (en) 2007-05-24
US7601809B2 (en) 2009-10-13
AU2002241533A1 (en) 2002-06-11
DE60140213D1 (de) 2009-11-26
CY1110921T1 (el) 2015-06-10
US20120064571A1 (en) 2012-03-15
US20070048804A1 (en) 2007-03-01
US7608452B2 (en) 2009-10-27
US20140248661A1 (en) 2014-09-04
JP2004532611A (ja) 2004-10-28
PT1356046E (pt) 2010-03-09
CA2430485A1 (en) 2002-06-06
EP1356046B1 (de) 2009-10-14
US20110091876A1 (en) 2011-04-21
DK1356046T3 (da) 2010-03-01
US20070111942A1 (en) 2007-05-17
US20070048799A1 (en) 2007-03-01
US20050266485A1 (en) 2005-12-01
US20070048846A1 (en) 2007-03-01

Similar Documents

Publication Publication Date Title
DK1356046T3 (da) Cytokinreceptor zcytoR19
WO2002000721A3 (en) Cytokine receptor zcytor17
DK1303602T3 (da) Oplöselige zalpha11 cytokinreceptorer
NZ510744A (en) Cytokine receptor zalpha11
UA84387C2 (ru) Человеческий цитокин как лиганд зальфа рецептора и его применение
Kao et al. A peptide derived from the amino terminus of endothelial-monocyte-activating polypeptide II modulates mononuclear and polymorphonuclear leukocyte functions, defines an apparently novel cellular interaction site, and induces an acute inflammatory response
WO2002012345A3 (en) Soluble zcytor 11 cytokine receptors
ATE371735T1 (de) Hematopoietischer zytokin rezeptor
IL163067A (en) Isolated heterodimeric cytokine receptor
ATE273384T1 (de) Tie-2 liganden, herstellungsverfahren und verwendung
DE69837996D1 (de) Tumornekrosefaktor-rezeptoren 6 alpha& 6 beta
DE69717664D1 (de) Protein e25a, methoden zu dessen herstellung und anwendung
ATE294236T1 (de) Promotor der tie rezeptor protein kinase
PT877803E (pt) Receptor da proteina ob e composicoes e metodos afins
MXPA03000227A (es) Compuestos novedosos.
DK1021534T3 (da) Hepatitis C-receptorprotein CD81
NO993653D0 (no) Fremgangsmåte for diagnose, prognose og behandling av glaukom og relaterte sykdommer
TR200000416T2 (tr) Neisseria loctoferrin bağlayıcı protein.
DE60117788D1 (de) Menschliche wingless-änhliche gene
Motozawa et al. Functional comparison of high and low molecular weight basic fibroblast growth factors
EP1736545A3 (de) Lösliche Zcyctor 11 Cytokinrezeptoren
UA84540C2 (en) Novel cytokine zcytor17 ligand

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1356046

Country of ref document: EP